# systemic lupus erythematosus FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/systemic-lupus-erythematosus

> 12 upcoming FDA catalysts in systemic lupus erythematosus: ianalumab (NVS) on Mar to Jun 2027 (topline data readout); RINVOQ® (upadacitinib, ABBV) on March 2027 (primary completion); RINVOQ® (upadacitinib, ABBV) on Mar to Jun 2027 (topline data readout); ianalumab (NVS) on March 2027 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2024 | [NKX019 trial start](https://sec-api.dev/pdufa/nkx019) | NKTX | systemic lupus erythematosus | completed | "In November 2024, we announced the first patient was dosed in our Ntrust-1 clinical trial ("Ntrust-1"), a multi-center, open-label, dose-escalation Phase 1 clinical trial of NKX019 for LN and the first patient was dosed in the IST of NKX019 for SLE at Columbia University Irving Medical Center." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1787400/000095017025045262/nktx-20241231.htm)) |
| mid-2025 | [ALLO-329 trial start](https://sec-api.dev/pdufa/allo-329) | ALLO | systemic lupus erythematosus | scheduled | "We expect to initiate the Phase 1 trial with ALLO-329 in mid-2025 and anticipate having proof-of-concept by the first half of 2026 to enable inclusion of both biomarker and clinical data." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000064/allo-20250331.htm)) |
| mid-2025 | [ATA3219 interim data readout](https://sec-api.dev/pdufa/ata3219) | ATRA | systemic lupus erythematosus | scheduled | "Atara expects to initiate a Phase 1 study of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]) by end of year with initial clinical data anticipated in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| mid-2025 | [ATA3219 trial start](https://sec-api.dev/pdufa/ata3219) | ATRA | systemic lupus erythematosus | scheduled | "Atara expects to initiate a Phase 1 study of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]) by end of year with initial clinical data anticipated in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| July 30, 2025 | [MK-6194 primary completion](https://sec-api.dev/pdufa/mk-6194) | MRK | Systemic Lupus Erythematosus | withdrawn | "NCT06161116 (Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161116)) |
| August 22, 2025 | [MEDI-546 primary completion](https://sec-api.dev/pdufa/medi-546) | AZN | Systemic Lupus Erythematosus | completed | "NCT04877691 (Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04877691)) |
| October 8, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Systemic Lupus Erythematosus | completed | "NCT05856448 (A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-08 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05856448)) |
| November 13, 2025 | [Cartesian Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/rnac/catalysts) | RNAC | systemic lupus erythematosus | completed, positive | "FREDERICK, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus (SLE)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/pressrelease11132025.htm)) |
| September 2026 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Systemic Lupus Erythematosus | delayed | "NCT06559163 (A Study of Obexelimab in Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559163)) |
| September 4, 2026 | [Sar441344 iv primary completion](https://sec-api.dev/pdufa/sar441344-iv) | SNY | Systemic Lupus Erythematosus | completed | "NCT05039840 (Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05039840)) |
| Sep to Dec 2026 | [Sar441344 iv topline data readout](https://sec-api.dev/pdufa/sar441344-iv) | SNY | Systemic Lupus Erythematosus | scheduled | "NCT05039840 (Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05039840)) |
| Q4 2026 | [Obexelimab topline data readout](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Systemic Lupus Erythematosus | scheduled | "Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm)) |
| Oct 2026 to Jan 2027 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | scheduled | "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05617677)) |
| Oct 2026 to Jan 2027 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | scheduled | "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05620407)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05617677)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05620407)) |
| Mar to Jun 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05639114 (Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639114)) |
| March 2027 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Systemic Lupus Erythematosus | scheduled | "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05843643)) |
| Mar to Jun 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Systemic Lupus Erythematosus | scheduled | "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05843643)) |
| March 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05639114 (Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639114)) |
| Apr to Jul 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05624749 (Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624749)) |
| April 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05624749 (Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624749)) |
| Oct 2028 to Jan 2029 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT05835310 (An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05835310)) |
| October 2028 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT05835310 (An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05835310)) |
| Jan to Apr 2029 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07430306 (A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430306)) |
| January 2029 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07430306 (A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430306)) |
| Sep to Dec 2030 | [Anifrolumab + apfs topline data readout](https://sec-api.dev/pdufa/anifrolumab-apfs) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07630714 (A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07630714)) |
| September 2030 | [Anifrolumab + apfs primary completion](https://sec-api.dev/pdufa/anifrolumab-apfs) | AZN | Systemic Lupus Erythematosus | scheduled | "NCT07630714 (A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07630714)) |

## Drugs

- [NKX019](https://sec-api.dev/pdufa/nkx019) (NKTX)
- [ALLO-329](https://sec-api.dev/pdufa/allo-329) (ALLO)
- [ATA3219](https://sec-api.dev/pdufa/ata3219) (ATRA)
- [MK-6194](https://sec-api.dev/pdufa/mk-6194) (MRK)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/systemic-lupus-erythematosus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "systemic lupus erythematosus FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/systemic-lupus-erythematosus

```bibtex
@misc{secapidev_indications_systemic_lupus_erythematosus_20261116,
  title        = {systemic lupus erythematosus FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/systemic-lupus-erythematosus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_systemic_lupus_erythematosus_20261116","title":"systemic lupus erythematosus FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/systemic-lupus-erythematosus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
